LAP Antibody (J-17A): sc-80151

LAP Antibody (J-17A) is a mouse monoclonal IgG1 kappa light chain antibody that detects LAP protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). LAP (J-17A) antibody is available as the non-conjugated anti-LAP antibody, providing researchers with a reliable tool for studying the dynamics of the transforming growth factor beta (TGFβ) superfamily. LAP protein plays a crucial role in regulating the activity of TGFβ, which is essential for various biological processes, including embryonic development, immune response, and tissue repair. LAP acts as a latency-associated peptide that binds non-covalently to mature TGFβ, preventing interaction with receptors until appropriate signals for activation are received. This regulatory mechanism is vital for maintaining tissue homeostasis and preventing excessive cellular responses that could lead to pathological conditions. Anti-LAP antibody (J-17A) enables researchers to gain insights into the intricate balance of TGFβ signaling pathways and their implications in health and disease, making LAP (J-17A) monoclonal antibody an invaluable asset for studies in developmental biology, cancer research, and fibrosis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LAP Antibody (J-17A) References:

1. Binding of TGF-beta1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells.  |  Thomas, GJ., et al. 2002. Br J Cancer. 87: 859-67. PMID: 12373600
2. Reverse transformation of hepatic myofibroblast-like cells by TGFbeta1/LAP.  |  Isono, M., et al. 2003. Biochem Biophys Res Commun. 311: 959-65. PMID: 14623275
3. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.  |  Zhang, Y., et al. 2003. J Invest Dermatol. 121: 713-9. PMID: 14632186
4. P311 binds to the latency associated protein and downregulates the expression of TGF-beta1 and TGF-beta2.  |  Paliwal, S., et al. 2004. Biochem Biophys Res Commun. 315: 1104-9. PMID: 14985127
5. Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1.  |  Annes, JP., et al. 2004. J Cell Biol. 165: 723-34. PMID: 15184403
6. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation.  |  Hyytiäinen, M., et al. 2004. Crit Rev Clin Lab Sci. 41: 233-64. PMID: 15307633
7. Amino acid requirements for formation of the TGF-beta-latent TGF-beta binding protein complexes.  |  Chen, Y., et al. 2005. J Mol Biol. 345: 175-86. PMID: 15567420
8. Latency associated peptide has in vitro and in vivo immune effects independent of TGF-beta1.  |  Ali, NA., et al. 2008. PLoS One. 3: e1914. PMID: 18392110
9. Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis.  |  Chen, ML., et al. 2008. J Immunol. 180: 7327-37. PMID: 18490732
10. Targeting latency-associated peptide promotes antitumor immunity.  |  Gabriely, G., et al. 2017. Sci Immunol. 2: PMID: 28763794
11. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.  |  Ye, R., et al. 2022. Cancer Immunol Immunother. 71: 301-310. PMID: 34152439
12. Latency-associated peptide (LAP)+CD4+ regulatory T cells prevent atherosclerosis by modulating macrophage polarization.  |  Yu, J., et al. 2023. Clin Immunol. 255: 109767. PMID: 37689092

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-LAP Antibody (J-17A) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-LAP Antibody (J-17A) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

LAP Antibody (J-17A) Specifications

Alternate Product Name: LAP

Product Clone Name: J-17A

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: LAP

Epitope Species: human

Product Reactivity/Detection: the LAP (latency associated peptide) of TGFβ1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, ELISA

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and protein stabilizer

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for LAP Antibody (J-17A): N/A